Health-related quality of life of HIV-infected patients taking different antiretroviral regimens at a tertiary healthcare facility in northern Nigeria
Purpose: To evaluate the health-related quality of life (HRQoL) of patients taking different antiretroviral regimens.
Methods: A cross-sectional descriptive design was used to evaluate HRQoL of patients on Highly Active Antiretroviral Therapy (HAART) at Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, Nigeria. Data were collected using HIV/AIDS-Targeted Quality of Life instrument between May and November, 2015 from 872 adult outpatients who had been on their regimen for at least 6 months. Data were statistically analysed.
Results: The overall HRQoL score of the patients was 59.40 ± 18.66. Among patients on the first-line regimens, those on TDF + FTC + EFZ (60.52 ± 19.17) and those on TDF + 3TC + EFZ (64.41 ± 18.04) reported the best HRQoL scores. The difference between the scores of patients on the two most utilised regimens; AZT + 3TC + NVP (58.14 ± 18.53) and TDF + 3TC + EFZ (64.41 ± 18.04) was significant (p < 0.05). Among patients on second-line regimens, those on TDF + FTC + LPVr (67.58 ± 14.80) reported the highest HRQoL score.
Conclusion: Patients in this facility had a moderate HRQoL. TDF + 3TC + EFZ, TDF + FTC + EFZ and TDF + FTC + LPVr were the regimens with the best HRQoL outcomes. The use of these regimens should be encouraged for better patient well-being.
Keywords: HIV, Health-related quality of life, Antiretroviral therapy, First-line antiretroviral regimen, Second-line antiretroviral regimen
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.